

**TARGETING REGULATORY PATHWAYS OF  
*STIMI* IN NASOPHARYNGEAL CANCER**

**OKEKPA SIMON IMAKWU**

**UNIVERSITI SAINS MALAYSIA**

**2021**

**TARGETING REGULATORY PATHWAYS OF  
*STIMI* IN NASOPHARYNGEAL CANCER**

by

**OKEKPA SIMON IMAKWU**

**Thesis submitted in fulfilment of the requirements  
for the degree of  
Doctor of Philosophy**

**October 2021**

## ACKNOWLEDGEMENT

I wish to express my appreciation to God almighty for granting me the grace and enablement to complete this program. I would like to thank the Tertiary Education trust fund Nigeria, and Ebonyi State University, Abakaliki. We would like to acknowledge the funding from Ministry of Higher Education for Fundamental Research Grant Scheme with project Code: FRGS/1/2019/skk15/USM/02/2 and Universiti Sains Malaysia for all the support and facilities. I also wish to thank my supervisor Dr. Rabiatul Basria S. M. N. Mydin for her advice and guidance throughout my research activities. Am also grateful to my co-supervisors Dr. Emmanuel Jairaj Moses, Dr. Muhamad Yusri Bin Musa, and Professor Dr. Gurjeet Kaur A/P Chatar Singh for excellent supervision and guidance. I also appreciate all the science officers, medical laboratory technicians, administrative staff, and every other staff of Advanced Medical and Dental Institute, USM that contributed to the success of my program. Thanks to all my lab-mates for being part of my success. The memories of the tears, frustrations, and joyous moments we shared together will remain indelible in my life. A very big thank you to my wife Okekpa Ijeoma Peace, my Kids Praise Chikamso Simon Okekpa, Serena Chiemerie Simon Okekpa and Diamond Chioma Simon Okekpa. I also wish to appreciate the effort of my late father Mr. John Udu Okekpa, my mother, Chinwe Ogodo Okekpa for their good parenting. I also appreciate my siblings (Oluchi, Ngozi, Chidimma, Uchenna, Udoka and Anayo), and loved ones for their care, support, and special prayers. Special thanks to my In-laws, late elder Ephraim Onwe, Ezinne Rebecca Onwe, Prof. Onwe Sunday Onwe, Rev., Samuel Onwe, Onwe Chika, Onwe Friday, Onwe Chukwuka, Onwe Uchenna and Chukwudi Onwe for their encouragement, financial support, and prayers.

## TABLE OF CONTENTS

<b>ACKNOWLEDGEMENT .....</b>	<b>ii</b>
<b>TABLE OF CONTENTS.....</b>	<b>iii</b>
<b>LIST OF TABLES .....</b>	<b>viii</b>
<b>LIST OF FIGURES .....</b>	<b>ix</b>
<b>LIST OF SYMBOLS .....</b>	<b>xii</b>
<b>LIST OF ABBREVIATIONS.....</b>	<b>xiii</b>
<b>LIST OF APPENDICES.....</b>	<b>xvi</b>
<b>ABSTRAK.....</b>	<b>xvii</b>
<b>ABSTRACT .....</b>	<b>xix</b>
<b>CHAPTER 1 INTRODUCTION.....</b>	<b>1</b>
1.1 Research background.....	1
1.2 Problem statement.....	2
1.2 Objectives .....	3
<b>CHAPTER 2 LITERATURE REVIEW .....</b>	<b>4</b>
2.1 Nasopharyngeal cancer (NPC) .....	4
2.1.1 Global prevalence and mortality of NPC .....	6
2.1.2 NPC situation in Malaysia .....	7
2.1.3 Risk factors of NPC .....	9
2.1.4 Clinical features, diagnosis and treatment of NPC.....	12
2.1.5 Limitations of current NPC treatment.....	14
2.1.6 Histopathological classification of NPC .....	14
2.1.7 Molecular dysregulation in NPC .....	16
2.1.8 NPC pathogenesis model .....	18
2.1.9 Oxidative stress and cellular homeostasis.....	20
2.2 Structure of STIM1 .....	21

2.2.1	STIM1 calcium signaling and cancer .....	23
2.2.2	Cross talk between STIM1, calcium and ROS.....	29
2.2.3	Oxidative stress and calcium signaling relationship with STIM1....	34
2.3	RNA interference (RNAi) tools .....	36
2.3.1	Small interfering-RNA (siRNA) .....	37
2.3.2	Dicer substrate Small interfering (DsiRNA) .....	39
2.4	MicroRNAs (miRNAs) .....	41
2.4.1	miRNA and NPC .....	43
<b>CHAPTER 3 METHODOLOGY.....</b>		<b>45</b>
3.0	Introduction.....	45
3.1.	Chemical reagents .....	45
3.2	Experimental workflow .....	46
3.3	Maintenance and establishment of cell line model .....	47
3.4	Bioinformatic analyses .....	50
3.4.1	Screening for target gene via KEGG .....	50
3.4.2	miRNAs targeted by genes using miRNet 2.0 .....	52
3.5	STIM1 Gene expressions in cell lines.....	52
3.5.1	Cell culture and treatment and RNA extracton .....	52
3.5.2	Reverse transcription .....	54
3.5.3	Real time quantitative polymerase chain reaction .....	55
3.6	STIM1 knockdown profiles .....	58
3.6.1	Determination of transfection success .....	58
3.6.2	Time and target point dependent STIM1 knockdown .....	58
3.7	Transcriptomic analyses .....	60
3.8	Post-transcriptional analyses.....	61
3.9	Functional Assay.....	63
3.9.1	Cell proliferations .....	63

3.9.2	Cell migrationon .....	64
3.9.3	Colony formation assay .....	64
3.10	Biochemical analyses .....	65
3.10.1	Determination of intracellular calcium levels .....	65
3.10.2	Calcium deposition profiles .....	65
3.10.3	Reactive oxygen specie profiles .....	67
3.11	Protein analyses.....	67
3.11.1	Western blot .....	68
3.11.2	Determination of Protein concentration .....	69
3.11.3	Preparation of SDS-PAGE resolving and stacking gels .....	70
3.11.4	Electrophoresis and immunoblotting .....	72
3.11.5	Immunohistochemistry.....	74
3.12	Statistical analyses.....	75
	<b>CHAPTER 4 RESULTS .....</b>	<b>76</b>
4.1	Target gene analyses.....	76
4.2	Bioinformatics analyses.....	78
4.3	Transcriptomic analysis .....	83
4.3.1	Expression of STIM1 in cell lines .....	83
4.3.2	Assessment of transfection success .....	84
4.3.3	Time dependent STIM1 knockdown and target point optimisation ..	85
4.3.4	Effect of GC content and target site DsiRNA knockdown .....	88
4.4	Transcriptional analysis .....	89
4.4.1	Effect of STIM1 knockdown on the calcium pathway .....	89
4.4.2	Effects of STIM1 knockdown on the PI3K/AKT pathway.....	90
4.4.3	Effects of STIM1 knockdown on the cell cycle pathway .....	92
4.4.4	Effects of STIM1 knockdown on the apoptotic pathway .....	94
4.5	Post-transcriptional analyses.....	96

4.6	Functional Assay Analyses .....	99
4.6.1	Effect of STIM1 knockdown on cell proliferation .....	100
4.6.2	Effect of STIM1 knockdown on cell Migration .....	101
4.6.3	Effect of STIM1 knockdown on colony formation .....	104
4.6.4	Effect of STIM1 knockdown on intracellular calcium levels .....	106
4.6.5	Effect of STIM1 knockdown on calcium deposition profile.....	108
4.6.6	Effect of STIM1 knockdown on ROS profiles.....	110
4.7	Protein analyses.....	112
4.7.1	Western blot .....	112
4.7.2	Immunohistochemistry.....	116
<b>CHAPTER 5 DISCUSSIONS .....</b>		<b>118</b>
5.1	STIM1 Expression and efficiency of DsiSTIM1 knockdown .....	118
5.2	Molecular profile at transcriptional level .....	121
5.2.1	Apoptotic signalling pathway.....	121
5.2.2	Calcium signalling Pathway.....	124
5.2.3	PI3K/AKT signalling pathway .....	126
5.2.4	Cell cycle signalling pathway.....	127
5.2.5	STIM1 knockdown at post-transcriptional level .....	128
5.3	Functional roles of <i>STIM1</i> knockdown .....	131
5.4	Posttranslational effect of STIM1 knockdown in NPC .....	137
5.4.1	STIM1 expression status in clinical samples .....	139
5.5	Proposed regulatory roles of STIM1 in NPC.....	140
<b>CHAPTER 6 CONCLUSIONS, AND FUTURE PERSPECTIVES .....</b>		<b>125</b>
6.1	Conclusion .....	143
6.2	Future perspectives .....	146

**REFERENCES ..... 147**

**APPENDICES**

**LIST OF PUBLICATIONS**



## LIST OF TABLES

	<b>Page</b>
Table 2.1 Classification, stages, and treatment of NPC.....	15
Table 2.2 Effect of deregulated STIM1 expression in various cancers.....	28
Table 3.1 RT-qPCR reaction setup.....	56
Table 3.2 RT-qPCR thermocycling procedure .....	56
Table 3.3 Primer sequences for the genes.....	57
Table 3.4 BSA standard assay for protein quantification.....	70
Table 3.5 Resolving gel preparation .....	71
Table 3.6 Stacking gel preparation.....	71
Table 3.7 Antibodies and their dilutions.....	73
Table 4.1 Absolute STIM1 expression in NPC cells.....	83
Table 4.2 Effect of percentage GC content and target site on DsiRNA mediated knockdown.....	88

## LIST OF FIGURES

	<b>Page</b>
Figure 2.1	Diagram showing the endoscopy and location of NPC..... 5
Figure 2.2	NPC pathogenesis model ..... 19
Figure 2.3	Structure of STIM1 and its luminal domain ..... 22
Figure 2.4	Molecular mechanism of STIM1 signaling ..... 25
Figure 2.5	STIM1 and Ca <sup>2+</sup> signaling pathway ..... 35
Figure 2.6	Molecular pathway for SiRNA gene silencing ..... 38
Figure 3.1	Experimental workflow showing research method for the study ..... 46
Figure 3.2	Haemocytometer showing grids..... 49
Figure 3.3	KEGG pathway analysis of genes in different pathways ..... 51
Figure 3.4	Flow chart for reverse transcription ..... 54
Figure 4.1	STIM1 and its associated genes/pathways from KEGG ..... 77
Figure 4.2.	Venn diagram of miRNA interaction with Pi3k/Akt pathway ..... 79
Figure 4.3	Venn diagram of miRNAs interaction with cell cycle genes ..... 80
Figure 4.4	Venn diagram of miRNAs interaction with apoptosis genes..... 81
Figure 4.5	Venn diagram of miRNAs interaction with Ca <sup>2+</sup> pathway genes ..... 82
Figure 4.6	STIM1 expression in cell lines ..... 84
Figure 4.7	Transfection success determined by fluorescence of nontargeting control ..... 85
Figure 4.8	Time dependent DsiRNA mediated <i>STIM1</i> knockdown ..... 87
Figure 4.9	Expression in of genes in calcium pathway signaling after <i>STIM1</i> knockdown ..... 90
Figure 4.10	Expression in of genes in calcium pathway signaling after <i>STIM1</i> knockdown ..... 91

Figure 4.11	Expression of genes in PI3K/AKT signaling pathway of HK1.....	92
Figure 4.12	Expression of genes in PI3K/AKT signaling pathway of C666-1 ....	93
Figure 4.13	Expression of genes in cell cycle pathway of HK1/NPC after STIM1 knockdown .....	93
Figure 4.14	Expression of genes in cell cycle pathway of C666-1/NPC after STIM1 knockdown .....	94
Figure 4.15	Gene expression in apoptotic pathway of HK1/NPC after STIM1 knockdown .....	95
Figure 4.16	Gene expression in apoptotic pathway of C666-1/NPC after STIM1 knockdown .....	96
Figure 4.17	Post-transcriptional expression in HK1/NPC after STIM1 knockdown .....	97
Figure 4.18	Post-transcriptional expression in C666-1/NPC after STIM1 knockdown .....	98
Figure 4.19	Effects of <i>STIM1</i> knockdown on HK1/NPC cell proliferation.....	99
Figure 4.20	Effects of <i>STIM1</i> knockdown on C666-11/NPC cell proliferation..	100
Figure 4.21	Effects of STIM1 knockdown on the HK1/NPC migrationin.....	102
Figure 4.22	Effects of STIM1 knockdown on the C666-1/NPC migration.....	103
Figure 4.23	Effects of STIM1 knockdown on the colony formation ability of HK1/NPC .....	104
Figure 4.24	Effects of STIM1 knockdown on the colony formation ability of C666-1/NPC .....	105
Figure 4.25	Intracellular Ca <sup>2+</sup> levels in HK1/NPC after STIM1 knockdown.....	106
Figure 4.26	Intracellular Ca <sup>2+</sup> levels in C666-1/NPC after STIM1 knockdown.	107
Figure 4.27	Ca <sup>2+</sup> deposition profile in HK1/NPC after STIM1 knockdown.....	108

Figure 4.28	Ca <sup>2+</sup> deposition profile in C666-1/NPC after STIM1 knockdown..	109
Figure 4.29	ROS generation in HK1/NPC after STIM1 knockdown.....	110
Figure 4.30	ROS generation in C666-1/NPC after STIM1 knockdown.....	111
Figure 4.31	Coomassie blue stain for protein bands .....	112
Figure 4.32	Expression of STIM1 protein after STIM1 knockdown.....	113
Figure 4.33	Expression of RAC1 protein after STIM1 Knockdown.....	114
Figure 4.34	Expression of ORAI1 protein after STIM1 knockdown .....	114
Figure 4.35	Expression of FOXO3a protein after STIM1 knockdown.....	115
Figure 4.36	Expression of CDKN1B protein after STIM1 knockdown .....	115
Figure 4.37	Photomicrograph for <i>STIM1</i> immunohistochemical staining.....	117
Figure 5.1	Overall Model of the STIM1 signaling .....	120
Figure 5.2	Effect of <i>STIM1</i> knockdown in the apoptotic pathway.....	123
Figure 5.3	Effect of <i>STIM1</i> knockdown. on Ca <sup>2+</sup> signaling.....	125
Figure 5.4	Effect of <i>STIM1</i> knockdown on PI3K/AKT pathway.....	126
Figure 5.5	Regulatory roles of STIM1 in HK1/NPC cells .....	141
Figure 5.6	Regulatory roles of STIM1 in C666-1 cells.....	142

## LIST OF SYMBOLS

$\alpha$	Alpha
$\beta$	Beta
G	Gram
$^{\circ}\text{C}$	Degree Celsius
kDa	Kilodalton
$\mu\text{g}$	microgram
$\mu\text{g/mL}$	Microgram/milliter
$\mu\text{L}$	Microliter
$\mu\text{M}$	Micromolar
mg	milligram
ml	microliters
mM	Millimolar
mL	Milliliter
ng	nanogram
Nm	Nanometer
%	Percentage
Rpm	Revolutions per minute
RT	Room temperature
V	Volt
w/v	Weight/volume

## LIST OF ABBREVIATIONS

Ago2	Argonaute 2
<i>AKT 1</i>	RAC-alpha serine/threonine-protein kinase
ATCC	American Type Culture Collection
<i>ATP2A2</i>	ATPase Sarcoplasmic/Endoplasmic Reticulum Ca <sup>2+</sup> Transporting 2
β-actin	beta actin
<i>BCL 2</i>	B-cell lymphoma 2
BSA	Bovine serum albumin
carboxy-	carboxy 2',7'-dichlorodihydrofluorescein diacetate
H2DCFDA	
<i>CDKN1B</i>	Cyclin-dependent kinase inhibitor 1B
cDNA	complementary DNA
CO <sub>2</sub>	carbon dioxide
CRC	Colorectal cancer
diH <sub>2</sub> O	deionized H <sub>2</sub> O
DMSO	Dimethyl sulfoxide
DsiRNA	Dicer-Substrate Short Interfering RNAs
dsRNA	Double-stranded RNA
dsRNA	double stranded RNA
DPBS	Dulbecco phosphate buffered-saline
EBV	Epstein-Barr virus.
<i>CDH1</i>	E-cadherin
EDTA	Ethylenediaminetetraacetic acid

EMT	Epithelial mesenchymal transition
ER	endoplasmic reticulum
ESCC	Esophageal squamous cell carcinoma
<i>GAPDH</i>	Glyceraldehyde 3-phosphate dehydrogenase
GC	Guanin cytosine
H2DCFDA	2',7'-dichlorodihydrofluorescein diacetate
<i>HPRT-1</i>	Hypoxanthine-guanine phosphoribosyl transferase
HRP	horseradish peroxidase
IHC	Immunohistochemistry
IP3	inositol triphosphate
KEGG	KEGG: Kyoto Encyclopedia of Genes and Genomes
<i>LTBR</i>	Lymphotoxin beta receptor
miRNA	MicroRNA
mRNA	messenger RNA
mPTPs	mitochondrial-permeability-transition pores
NCBI	National Centre for Biotechnology Information
NPC	Nasopharyngeal cancer
<i>ORAI1</i>	Calcium release-activated calcium channel protein 1
PAGE	Polyacrylamide Gel Electrophoresis
PBS	phosphate buffered saline
PCR	Polymerase chain reaction
PI3K/Akt	Phosphatidylinositol 3-kinase/protein kinase-B
<i>PIK3CA</i>	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha
PVDF	poly-vinylidene difluoride
<i>Rac1</i>	Ras-related C3 botulinum toxin substrate 1

RIPA	Radio-immunoprecipitation assay
RISC	RNA induced silencing complex
RNA	Ribonucleic acid
RNA	Ribonucleic acid
RNAi	RNA interference
RNP	Ribonucleotide protein complex
ROS	Reactive oxygen species
RT-qPCR	Real-time quantitative polymerase chain reaction
<i>RYR2</i>	Ryanodine receptor 2
SDS	Sodium dodecyl sulfate
SDS-PAGE	SDS-polyacrylamide gel electrophoresis
siRNA	Small interfering RNA
<i>SKP2</i>	S-phase kinase-associated protein 2
<i>STIM1</i>	Stromal interaction molecule1
TAR	Trans-activation response
TBS	Tris buffered saline
TBS	Tris-buffered saline
TBST	Tris buffered saline tween
TEMED	Tetra methyl ethylene diamine
TGF- $\beta$ 1	Transforming growth factor beta 1
UTRs	Untranslated regions
VOCs	voltage-operated channels



## **LIST OF APPENDICES**

APPENDIX A	miRNAs target involved in PI3K/AKT pathway
APPENDIX B	miRNAs targets involved in cell cycle pathway
APPENDIX C	miRNA targets involved in apoptotic pathway
APPENDIX D	miRNA target involved in calcium pathway
APPENDIX E	Expression of STIM1 in cell lines
APPENDIX F	Ethical approval
APPENDIX G	List of publications And Scientific presentations

# MENSASARKAN PENGAWALATURAN *STIMI* DAN LALUANNYA DALAM KANSER NASOFARINKS

## ABSTRAK

Molekul interaksi stromal 1 (*STIMI*) terlibat dalam pelbagai proses karsinogenik. Walau bagaimanapun, penglibatan dan implikasi molekul *STIMI* dalam kanser nasofarinks (NPC) tidak difahami sepenuhnya. Kajian ini bertujuan untuk menyelidiki peranan pengawalseliaan *STIMI* dan laluan isyarat yang berkaitan di Kanser nasofarinks, menggunakan model penyah fungsian gen yang dimediasi DsiRNA. Titis-titis sel NPC yang digunakan adalah sel-sel yang berkaitan dengan HK1/NPC-Non EBV dan C666-1/NPC EBV. Gen-gen dan laluan-laluan fungsian yang berkaitan dinilai melalui analisis bioinformatik. Ekspresi *STIMI* serta kesan transkripsi dan pasca-transkripsi penyahfungsian *STIMI* di titisan-titis sel NPC ditentukan melalui RT-qPCR. Peranan penyahfungsian *STIMI* dikaji dari segi percambahan sel, penghijrahan sel, kemampuan pembentukan koloni, profil kalsium dan aktiviti spesies oksigen reaktif. Kemudian, kesan pasca-terjemahan *STIMI* dalam NPC dikaji melalui Western blot dan pewarnaan imunohistokimia. Ekspresi *STIMI* yang rendah dalam HK1/NPC serta ekspresi *STIMI* yang tinggi dalam C666-1/NPC dapat dilihat berdasarkan perbezaan dalam patogenesis tumor NPC. Penyahfungsian *STIMI* yang optimum dicapai pada 12 jam dan berterusan selama 72 jam di HK1/NPC, sementara penyahfungsian *STIMI* yang optimum bagi C666-1/NPC dicapai pada 48 jam dan berterusan selama 72 jam. Penyahfungsian *STIMI* mengawal selia ekspresi *PIK3CA*, *AKT1*, *Orai1*, *BCL2* dan *SKP2*, yang dikaitkan dengan NPC. Penyahfungsian *STIMI* juga mengawal selia *BAX*, *P27*, *PTEN*, *RXR2*, *ATP2A2* dan *CDH1*, yang dikaitkan dengan perencatan NPC. Kajian kami menunjukkan penyenyapan *STIMI*

mampu mengawal selia ekspresi miRNA 205-3p, miRNA 185-5P, mir-34a-5p, let-7b-5p, miRNA 200a-3p dan miRNA375 setelah transkripsi, menunjukkan prognosis yang baik. Penyenyapan *STIMI* mengakibatkan penindasan protein-protein STIM1, RAC1 dan ORAI tetapi meningkatkan tahap protein-protein FOXO3a dan CDKN1B(P27). Analisis lanjutan terhadap pewarnaan imunohistokimia menunjukkan ekspresi sederhana *STIMI* dalam NPC bukan keratinising dibezakan, manakala NPC bukan keratinising tidak dibezakan menunjukkan intensiti pewarnaan yang kuat. Kesimpulannya, kajian ini mencadangkan *STIMI* mempunyai hubung-kait dengan kesan kawal-selia banyak laluan serta *STIMI* adalah sasaran yang berpotensi untuk NPC. Oleh itu, menilai hubungan antara parameter patologi klinikal terhadap tahap protein NPC dan STIM1 in vivo adalah sangat penting.

# TARGETING REGULATORY PATHWAYS OF STIM1 IN NASOPHARYNGEAL CANCER

## ABSTRACT

Stromal interaction molecule 1 (*STIM1*) is involved in various carcinogenic processes. However, the involvement and molecular implication of *STIM1* in nasopharyngeal cancer (NPC) is not fully understood. This study aims to investigate the regulatory roles of *STIM1* and associated signaling pathways in NPC, using a DsiRNA-mediated gene knockdown model. The NPC cell lines used were HK1/NPC-Non EBV- and C666-1/NPC EBV-related cells. Genes and related functional pathways were assessed through bioinformatics analysis. *STIM1* expression and the transcriptional- and post-transcriptional effects of *STIM1* knockdown in NPC cell lines were determined through RT-qPCR. The functional roles of *STIM1* knockdown were studied in terms of cell proliferation, cell migration, colony formation ability, calcium profiles and reactive oxygen species activities. Then, the post-translational effect of *STIM1* in NPC were studied through Western blot and immunohistochemical staining. Low *STIM1* expression in HK1/NPC and high *STIM1* expression in C666-1/NPC were observed because of differences in NPC tumour pathogenesis. Optimum *STIM1* knockdown was achieved at 12 h and sustained for 72 h in HK1/NPC, whereas optimum *STIM1* knockdown for C666-1/NPC was achieved at 48 h and sustained for 72 h. *STIM1* knockdown regulated the expression of *PIK3CA*, *AKT1*, *Orai1*, *BCL2* and *SKP2*, which were associated with NPC. *STIM1* knockdown regulated the expression of *BAX*, *P27*, *PTEN*, *RYR2*, *ATP2A2* and *CDH1*, which were associated with the inhibition of NPC. Our findings showed that *STIM1* silencing can regulate the expression of miRNA 205-3p, miRNA 185-5p, miR-34a-5p, let-7b-5p, miRNA 200a-3p and miRNA375 after transcription, indicating good prognosis. *STIM1* silencing resulted in the suppression of *STIM1*, *RAC1* and *Orai1*

proteins but increased FOXO3a and CDKN1B(P27) protein levels. Further analysis on immunohistochemical staining showed moderate STIM1 expression in non-keratinising differentiated NPC, and non-keratinising undifferentiated NPC showed strong staining intensity. In conclusion, this study suggests that STIM1 has an interlinking association with regulatory effect of many pathways and *STIM1* is a potential target for NPC. Thus, evaluating the association between the clinicopathological parameters of NPC and STIM1 protein levels in vivo is crucial.

## CHAPTER 1

### INTRODUCTION

#### 1.1 Research Background

Nasopharyngeal cancer (NPC) is commonly diagnosed at the advanced stage with poor prognosis. NPC treatment is complex because of NPC's multiple risk factors. The current treatment option for NPC is concomitant chemotherapy and radiation therapy. However, treatment of NPC at advanced stage is challenging and associated with high fatality rate. The risk factors associated with NPC are Epstein–Barr virus (EBV) infection, lifestyle, and dietary factors. In Malaysia, NPC ranked as the fourth most common cancer in 2020 with 2.222 new cases, 1.450 deaths, an age-standardised rate of 6.3 per 100,000 and an age-standardised mortality rate of 3.7 people per 100,000 (Lao and Le, 2020). NPC prognosis is poor because of late lesions, which are attributed to a poor understanding of its molecular pathogenesis. The pathophysiology of cancers and unsuccessful treatment are associated with oxidative stress responses (Biswas, 2016).

The association between the molecular mechanisms of NPC and oxidative stress is still not clear; therefore, understanding the relationship might provide a suitable therapeutic target for NPC. The deregulation of the oxidant equilibrium generates oxidative stress, which alters and damage intracellular molecules. High oxidative conditions trigger a deregulated endoplasmic reticulum (ER)  $\text{Ca}^{2+}$  release, which induces oxidation of proteins, DNA and lipids leading to cellular damage and impaired repair mechanism (Dai *et al.*, 2017). Therefore, understanding the molecular basis of ER stress in NPC and its interactions with  $\text{Ca}^{2+}$  pathways is necessary. Stromal interaction molecule 1 (STIM1) protein is a  $\text{Ca}^{2+}$  sensor that regulates calcium homeostasis and is consistently deregulated in various malignancies (Wang *et al.*, 2017).

STIM1 has two EF hand motifs of which one of the EF hand motifs binds  $\text{Ca}^{2+}$  while the second EF hand motif does not bind  $\text{Ca}^{2+}$  (Soboloff *et al.*, 2012). and associated with the regulation of mitochondrial bioenergetics and oxidative stress. Oxidative stresses are linked to increased reactive oxygen species (ROS) formation, the oncogenic signaling in cancer cells sustains ROS levels via the involvement of antioxidant activities. (Poprac *et al.*, 2017). Furthermore, the oncogenic activities of STIM1 in cancers occurs via aberrant expression, whereas its suppression inhibits cancer development (Xu *et al.*, 2015a; Zhang *et al.*, 2015). Previous studies reported that *STIM1* deregulation associated with induce hyperactivities in cancers, such as cell proliferation, migration, cell cycle alteration and inhibition in apoptosis (Yang *et al.*, 2013; Jardin *et al.*, 2018). Till date, the functions of STIM1 in NPC is not clear. Present work studied *STIM1* regulatory behavior using DsiRNA-mediated gene knockdown on NPC cell lines model; HK1/NPC-Non EBV- and C666-1/NPC EBV-related cells. Targeting STIM1 will provide an insight into the molecular effects especially oxidative stress, NPC pathophysiology and potential molecular target development that could prevention or reduce NPC cases.

## 1.2 Problem statement

1. STIM1 expression is altered in cancers. Previous evidence has revealed that deregulated *STIM1* expression contributes to tumorigenesis.
2. Deregulated expression of STIM1 in cancers results in elevated calcium influx which promotes carcinogenesis by increasing migration, colony formation. proliferation, cell cycle alteration, apoptosis inhibition and has been implicated in the promotion of cancer development.
3. The functions of STIM1 in NPC is largely unclear. Therefore, this study aims to examine the functional effects of *STIM1* expression in NPC.

### 1.3 Objectives

#### General objective:

To study the regulatory roles of STIM1 and its associated pathways in NPC.

#### Specific objectives

1. To evaluate the expression of *STIM1* in cell lines and determine the best target point, percentage GC content and time point for Dicer substrate small interfering RNA (DsiRNA)-mediated *STIM1* knockdown in NPC cell lines
2. To elucidate STIM1 regulatory pathways in NPC using bioinformatic platform.
3. To evaluate the effects of *STIM1* knockdown on the transcriptomic expression of genes in apoptosis, cell cycle, PI3K/AKT and calcium signalling pathways and the post-transcriptional effects of *STIM1* knockdown.
4. To assess the functional effects of *STIM1* on the cell proliferation, migration, colony formation ability, calcium deposition, intracellular calcium levels and reactive oxygen species (ROS) in NPC cell lines after *STIM1* knockdown
5. To determine the post-translational expression of STIM1, ORAI1, FOXO3a, RAC1 and CDKN1B proteins in NPC after *STIM1* knockdown
6. To evaluate the expression of STIM1 protein in NPC tissues.




## CHAPTER 2

### LITERATURE REVIEW

#### 2.1 Nasopharyngeal cancer

NPC is a highly metastatic cancer that arises at the nasopharynx, behind the nasal cavity and above the mouth (Tsao *et al.*, 2014; Tu *et al.*, 2016; Okekpa *et al.*, 2019) (Figure 2.1). NPC has dissimilar geographical distribution, and Asia has the highest NPC occurrence rate (Kontos *et al.*, 2013; Tu *et al.*, 2016; Mahdavifar *et al.*, 2016). The current treatment option for NPC is the combination of chemotherapy and radiotherapy (Colevas *et al.*, 2018). However, the success of NPC treatment depends on the NPC stage (tumour, node and metastasis [TNM] stages) (Tulalamba and Janvilisri, 2012; Colevas *et al.*, 2018). NPC treatment is mostly initiated at the advanced stages because of late diagnosis and partly because of insufficient knowledge about NPC's molecular pathogenesis (Hsu *et al.*, 2014).

NPC incidence is three folds more in males than female (Bray *et al.*, 2018; Hamid, 2021). The dominance of NPC incidence in males can be associated with gender and biological differences or dissimilarity in lifestyles and environmental factors, such as alcohol consumption, smoking and exposure to hazardous occupations (Jia and Qin, 2019). NPC incidence in low-risk groups increases with age because older people have higher susceptibility and are associated with more exposure to carcinogens early in life (Wang *et al.*, 2004; Schottenfeld, and Fraumeni, 2006). NPC takes years to metastasize after the appearance of the signs; thus, persistent exposure to carcinogens contributes to NPC development (Jia and Qin, 2019).



**Figure 2.1** NPC location observed using endoscopy approach. NPC is located at the nasopharynx, behind the nasal cavity and above the mouth (<https://imunews.imu.edu.my/wp-content/uploads/2015/03/Cancer-2.jpg> 10 September 2020).

### 2.1.1 Global prevalence and mortality of NPC

Globally, the prevalence of new NPC cases in 2018 was 129,079, amongst which 93,416 (72.37 %) are males and 35,663 (27.63 %) are females. In the same year, 72,987 individuals, including 54,280 (74.37 %) males and 18,707 (25.63 %) females, died from NPC. In Southeast Asia, 34,681 new NPC cases, which include 25,895 (74.67 %) men and 8,786 (25.33 %) women, were recorded in 2018; amongst these cases, 22,231 individuals, including 15,057 males and 5,174 females, died from NPC (Lao and Le, 2020). In Malaysia, NPC was rated the fifth most common cancer in 2020 with 2,222 new cases and 1,450 deaths (Lao and Le, 2020). NPC is not prevalent in Japan, Latin America, and most Western countries, wherein the occurrence rate of NPC is less than 1 per 100,000 people (Bray *et al.*, 2018).

Global NPC incidence is fewer than 1 for every 100,000 person in many years, but, Taiwan, has the incidence of about 2.8–6.6 for every 100,000 persons (Fan *et al.*, 2018). The five Asian countries with the highest standardised incidence of NPC are Brunei, Singapore, Indonesia, Malaysia and Vietnam, which have standardised NPC incidence rates of 9.9, 6.7, 6.6, 6.3 and 5.7 for every 100,000 people, respectively (Lao and Le, 2020). The five Asian countries with the highest NPC-related mortality are Brunei, Indonesia, Timor-Leste, Viet Nam and Malaysia, which have standardised rates of 5.8, 4.3, 4.0, 3.9 and 3.7 per 100,000 people, respectively (Lao and Le, 2020). In high NPC endemic areas, non-keratinizing-carcinoma (NKC) histotype of NPC is more prevalent whereas, keratinizing squamous-cell carcinoma (KSCC) histotype is more prevalent at low endemic risk regions (Carioli *et al.*, 2017).

### **2.1.2 NPC Situation in Malaysia**

NPC has been shown as one of the top five cancers in Malaysia Since 1966 (Linton *et al.*, 2021). In early 80s (1981 and 1982), NPC was recorded as the second most prevalent cancer in Sarawak males (AK, 1985; Linton *et al.*, 2021). Precisely, the incidence rate of NPC between January 1981 and December 1982, in Bidayuh, (formerly known as Land Dayak in Sarawak) was 9.0 per 100,000 for each year, while Sarawak Chinese had 5.8 per 100,000 (AK, 1985; Linton *et al.*, 2021). NPC was the most common cancer in the Sarawak males of Iban or Bidayuh ethnicity between 2007 to 2011 (Sarawak Cancer Registry, Malaysia, 2017). NPC became the fifth commonest cancer amongst Malaysian residents between 2012 to 2016 and predominantly found in male. It is the fourth most prevalent cancer in Chinese Malaysian males and has top incident rate in Sarawak males (Azizah *et al.*, 2019).

The prevalence rate of NPC in Sarawak doesn't reflect the incidence rate in other Malaysia states (Linton *et al.*, 2021). Other race in Malaysia such as Melanau, Malay and Chinese also have NPC risk. Age standardised rate (ASR) of NPC in Sarawak between 2007 to 2011 was 11.6 for every 100,000 population in males and 4.8 for every 100,000 in females, with ASR-ratio of 2.4:1 in male to female (Sarawak Cancer Registry, Malaysia, 2017). Precisely, in Bidayuh males the has 24.6 for every 100,000 and 9.3 per 100,000 for females (Sarawak Cancer Registry, Malaysia, 2017). The ASR at Iban was 12.0 for each 100,000 males and 4.7 for each 100,000 females. For the Chinese, there were 11.2 for every 100,000 males and 4.1 for every 100,000 of females. Malay males have 8.1 per 100,000 ASR and 4.5 per 100,000 ASR in females (Sarawak Cancer Registry, Malaysia, 2017).

Additionally, Melanau has ASR of 4.7 per 100,000 for males and 1.9 per 100,000 for females (Sarawak Cancer Registry, Malaysia, 2017). The incidence ratio of NPC in males is 2-3 folds higher than in females. In 2020, GLOBOCAN estimated that the world ASR was 2.2 per 100,000 and 0.8 per 100,000 for male and females respectively (Ferlay *et al.*, 2020). The higher prevalent rate of NPC in male than in females might be associated with susceptibility of the X-chromosome or oestrogen (Xie *et al.*, 2013; Zuo *et al.*, 2019), as well as lifestyle and environment factors (Tang *et al.*, 2016).

Previous study in NPC at Pahang referral hospitals Malaysia from 2012 to 2017 revealed that 143 new NPC cases were reported with ratio of 2.9 male to 1 female (Azizah *et al.*, 2017). Pahang has mean ASR of 2.4 per 100,000 for males and 0.9 per 100,000 for females (Ahmad *et al.*, 2021). Malaysian National Cancer Registry 2012-2011 reported that an average of 900–1,000 cases was obtained each year from 2007–2011 with ASR of 6.4 per 100,000 for males and 2.2 per 100,000 for females. The Malaysian ethnic nationality with higher ASR was Chinese males with AR of 11.0 per 100,000, Malay males with 3.3 per 100,000 and Indian males with 1.1 per 100,000 (Ahmad *et al.*, 2021).

### 2.1.3 Risk factors of NPC

NPC has a multifactorial risk factor, which includes race, EBV infection, genetic susceptibility, diet consumption, lifestyle, and environmental factors. Tobacco smoking, salted fish consumption, preserved food and alcohol consumption are remarkably associated with NPC risk (Jia *et al.*, 2010; Polesel *et al.*, 2013; He *et al.*, 2015; Lourembam *et al.*, 2015; Ren *et al.*, 2017; Yong *et al.*, 2017; Okekpa *et al.*, 2019; Okekpa *et al.*, 2020). A study reported that the prevalence rate of NPC can be increased by the consumption of nitrosamines in preserved foods, such as salted fish (Lo *et al.*, 2004; Chattopadhyay *et al.*, 2017). An increase in NPC prevalence is considerably associated with salted fish consumption (Zheng *et al.*, 1994; Kataki *et al.*, 2011; Yong *et al.*, 2017). The processes involved in the preservation of salted fish generates carcinogenic nitrosamines (Ekburanawat *et al.*, 2010; Chattopadhyay *et al.*, 2017; Yong *et al.*, 2017).

Nitrosamine performs oxidising activities in cells, which reduces the levels of intracellular glutathione (GSH), inhibit antioxidant activities, enhance lipid peroxidation and nitric oxide release, and create oxidative stress (Waly *et al.*, 2018). Meta-analysis revealed that salted fish consumption has remarkable association with NPC development (Yong *et al.*, 2017; Mydin and Okekpa, 2019). Multivariate analysis revealed that salted fish consumption substantially raises NPC risk (Yong *et al.*, 2017). Chinese style salted-preserved fish causes NPC, and its mechanism for carcinogenesis is mediated by exposure to N-nitrosamines, EBV reactivating constituents, direct geno-toxins, and mutagens ((IARC 2012; Chang *et al.*, 2021). Early childhood exposure to salted fish consumption and other N-nitrosamines containing food was linked with carcinogenesis of NPC because N-nitrosamines can activate latent EBV or act as an independent carcinogen (Mimi *et al.*, 1986; Mimi and Yuan, 2002).

NPC incidences increase with age in non-endemic regions while the in high-risk countries such as China, the highest NPC incidence occur at ages between 45 to 54 years. However, early exposure to EBV and carcinogens may cause younger NPC onset (Parkin *et al.*, 2002; Argirion *et al.*, 2020). In non-NPC endemic countries, frequent alcohol consumption and cigarette smoking was associated with the risk of keratinizing squamous-cell carcinoma (Vaughan *et al.*, 1996; Barrett *et al.*, 2019; Argirion *et al.*, 2020). Previous studies suggested that alcohol consumption increases NPC risk, and the frequency of alcohol consumption is positively associated with NPC risk (Du *et al.*, 2019; Mydin and Okekpa, 2019). Alcohol consumption is linked with NPC risk because the metabolite of alcohol called acetaldehyde binds to DNAs to form carcinogenic adducts (Seitz and Mueller, 2015; Mydin and Okekpa, 2019). Smoking is associated with squamous cell NPC. Tobacco smoke has also been linked to NPC risk because it contains high levels of nitrosamines (Xue *et al.*, 2013; Xie *et al.*, 2015; Ren *et al.*, 2017).

The carcinogenic mechanism of tobacco smoke occurs through the direct interaction between nasopharynx epithelium and chemicals in smoke. Long-term cigarette smoke inhalation is also associated with the high risk of developing keratinising NPC (Vaughan *et al.*, 1996; Chang *et al.*, 2017; Long *et al.*, 2017). The cell components of the NPC microenvironment enhance EBV infection (Huang *et al.*, 1999; Lin *et al.*, 2018). EBV infection was first associated with NPC when the serum of patients with NPC was found to show high titre against EBV antigens (Old *et al.*, 1966; Tsao *et al.*, 2017; Yang *et al.*, 2019). EBV infection is associated with non-keratinising and histologically undifferentiated NPC (Lo *et al.*, 2004; Tsang and Tsao, 2015; Tsao *et al.*, 2017; Lee *et al.*, 2021).

The molecular mechanisms of EBV in NPC pathogenesis results from the establishment of aberrant latent infection in the nasopharynx epithelium, which causes pre-malignant changes, such as the deletion of *p16* and the up-regulated expression of cyclin D1 (Tsang *et al.*, 2012; Cho *et al.*, 2020). Latent EBV genes regulate NPC growth to evade the immune system and suppress apoptosis (Tsao *et al.*, 2017; Lin *et al.*, 2018). Lytic EBV antigens, which are associated with NPC risk amongst Asian population, are stimulated through the medicinal use of traditional herbs (Hildesheim *et al.*, 1992; Yang *et al.*, 2019). Other factors associated with NPC risk are aerosolised toxic pollutants, such as formaldehyde, and wood dust, which cause nasopharyngeal irritation and consequent inflammation (Armstrong *et al.*, 1983; Chang and Adami, 2006; Li *et al.*, 2006; Bussu *et al.*, 2021). Many other studies have equally observed that wood dust exposure can cause nasal tumours (Hardell *et al.*, 1982; Armstrong *et al.*, 1983; Fang *et al.*, 2001; Hildesheim *et al.*, 2001; Ekpanyaskul *et al.*, 2015).

The link between wood and NPC tumourigenesis is attributed to the toxic chemicals used in wood preservation (Hardell *et al.*, 1982; Ekpanyaskul *et al.*, 2015). The regular consumption of salted vegetable can also increase NPC risk (Armstrong, Yu and Henderson, 1983; Turkoz *et al.*, 2011; Polesel *et al.*, 2013; Yong *et al.*, 2017; Okekpa *et al.*, 2019). Genetic predisposition was suggested as one of the main factors that contribute to the high NPC occurrence rate in Chinese population (Lu *et al.*, 2003; Lung *et al.*, 2019). The association between human leukocyte antigen (*HLA*) genes and NPC was studied by many researchers with controversial outcomes (Simons *et al.*, 1974; Chan *et al.*, 1985; Ren *et al.*, 1995). The first researcher to report the association between NPC risk and *HLA-A2* phenotype in Singaporean–Chinese population was (Simons *et al.*, 1974).



Further studies showed that people with *HLA* genes *BW46*, *AW19-B17*, *A2*, *A2-BW46*, *A2-B16*, *B17<sup>+</sup>*, *B18<sup>+</sup>* and *B35<sup>+</sup>* have increased NPC risk (Chan *et al.*, 1985; Ren, *et al.*, 1995; Lung *et al.*, 2019). The association of these *HLA* genes with NPC incidence led to the proposition that the *HLA* region may have a disease susceptibility gene that increases NPC risk (Chan *et al.*, 1985; Ren *et al.*, 1995; Ning *et al.*, 2020). The findings of genome-wide association studies showed a strong association of *HLA-A*, *HLA-B* and *HLA-C* with increased NPC susceptibility (Lu *et al.*, 1998; Salehiniya *et al.*, 2018). Individuals with *HLA-B\*55:02*, *HLA-A\*31:01*, *HLA-A\*11:01* and *HLA-B\*13:01* alleles have decreased NPC risk. The other genes that are also associated with high NPC risk are *MDS1-EVII*, *MICA*, *ITGA9*, *HCG9*, *CDKN2B*, *GABBR*, *TNFRSF19* and *HCP5* (Tse *et al.*, 2009, 2011; Bei *et al.*, 2010; Jia *et al.*, 2010). Genes that metabolise nitrosamine, such as *CYP2E1* and *CYP2A6*, are also susceptible to increased NPC risk (Cui *et al.*, 2016). Previous discoveries revealed that X-ray repair cross-complementing 1 (*XRCC1*) with genotype Trp194Trp is associated with decreased NPC risk in Cantonese tobacco smokers and males (Cao *et al.*, 2006).

#### **2.1.4 Clinical features, diagnosis, and treatment of NPC**

NPC manifests in multiple forms, but many patients present NPC at advanced stage with poor prognosis. Patients seek medical advice at a late stage, that is, patients first consult doctors at approximately 6 months after symptom appearance, because NPC has misleading and confusing symptoms and check-up of the nasopharynx is difficult to perform (Abdullah *et al.*, 2009; Waliyanti *et al.*, 2018). NPC has unspecific early symptoms, such as auditory complaints, neck masses, epistaxis, tinnitus, headache, nasal obstruction, facial numbness and hoarseness, which lead to late presentation and diagnosis (Abdullah *et al.*, 2009; Razak *et al.*, 2010; Tabuchi *et al.*, 2011; Waliyanti *et al.*, 2018).

NPC is metastatic; about 75 % of patients with NPC have neck lumps, and distant metastasis is the major cause of patient death (Chua *et al.*, 2016). NPC diagnosis requires postnasal mirror and naso-endoscopy to reveal exophytic tumour, but many NPCs are submucosal and complex to diagnose (Abdullah *et al.*, 2009). Current NPC diagnosis is via the pathological examination of biopsy specimens (Jeyakumar *et al.*, 2006). The erythrocyte sedimentation rate (ESR) and full blood count (FBC) of patients with NPC must be investigated to rule out repeated epistaxis and high ESR, which are symptoms of anemia and lymphoma, respectively (Abdullah *et al.*, 2009). Radiological examination is used to classify NPC based on TNM staging (Liu *et al.*, 2014; Lee *et al.*, 2019). NPC stage and tumour extension are assessed using magnetic resonance imaging (MRI) and computed tomography (CT) scans (Topkan *et al.*, 2020). Advancement in technology has brought 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography–CT for better NPC diagnosis, therapeutic assessment and prognostic assessment (Agarwal *et al.*, 2013; Topkan *et al.*, 2020).

Early-stage NPC is treated by radiotherapy. Intensity-modulated radiotherapy (IMRT) is preferred over conventional standard 2D radiotherapy as NPC treatment. IMRT is tumouricidal with minimum effect on adjacent healthy tissues (Luo *et al.*, 2016). The standard treatment for advanced NPC, particularly locoregional NPC, is concurrent chemoradiotherapy (Chua *et al.*, 2016; Handayani *et al.*, 2020; Topkan *et al.*, 2020). Fresh fruit, herbal tea and herbal soup consumption are associated with the reduction of NPC risk depending on the frequency of consumption (Jia *et al.*, 2010). Habitual tea consumption is linked to NPC prevention because of its polyphenolic content (Okekpa, *et al.*, 2020). A previous report established that polyphenols and antioxidant in tea prevents cancer development through enzyme inhibition (Martínez *et al.*, 2018).

### **2.1.5 Limitations of current NPC treatment**

The current NPC treatment is radiation-therapy combine with or without chemotherapy and Nasopharyngectomy. Nasopharyngectomy causes transient complications such as submandibular necrosis and palatal fistula (Bian *et al.*, 2012). Therapeutic challenge of radiation treatment is the determination of the radiation dose and normal organs tolerance. Mortality may also result from radiation-therapy due to excessive bleeding resulting from injury to the carotid artery (Hao *et al.*, 2008). Radiotherapy can cause adverse effects such as cranial nerve palsy, trismus, xerostomia, mucositis, necrosis of the nasopharynx, necrosis of the temporal lobe and hearing deficit (Bian *et al.*, 2012; Qiu *et al.*, 2014).

### **2.1.6 Histopathological classification of NPC**

NPC is classified into three subtypes depending on microscopic histological appearance (Table 2.1) and differentiation level (Handayani *et al.*, 2020). The classifications according to WHO are: keratinising squamous cell carcinoma, also known as type 1 and characterised by keratin protein production; differentiated nonkeratinizing carcinoma, also known as type 2 and undifferentiated carcinoma, also called type 3 (Barnes *et al.*, 2005; Chen *et al.*, 2019; Gondhowiardjo *et al.*, 2020). Histologically, type 1 NPC has keratinisation features with squamous and intercellular bridges (Sharif *et al.*, 2020). This type of NPC is graded into poorly or moderately differentiated. Types 2 and 3 are more common and have strong association with EBV such as Asia, whereas type 1 is not common in NPC endemic regions (Marcus and Tishler, 2010; Sharif *et al.*, 2020). Nonkeratinising differentiated NPC has similar histopathological appearances as undifferentiated NPCs, except that the cell borders of the former are stratified and paved (Chen *et al.*, 2019).

Undifferentiated NPC is microscopically characterised by spindle or oval shaped vesicular hyperchromatic nuclei, which possess protuberant nucleoli and mitotic activity (Wei *et al.*, 2010). However, the survival rate of patients with NPC depends on cancer stage (Table 2.1). For example, people with stage I or II NPC have 72 %–90 % 5-year survival rate, whereas those with stage III NPC have a 5-year survival rate of ~55 %. People with stage IV NPC have 30% survival rate because of frequent locoregional metastasis or recurrence (Tulalamba and Janvilisri, 2012; Chattopadhyay *et al.*, 2017).

**Table 2.1** Classification and stages of NPC. The table shows WHO classification of NPC for 1978, 1991 and 2005. It also showed stages of NPC and the treatment in the lower part of the table

<b>Classification of NPC (Barnes <i>et al.</i>, 2005)</b>		
<b>WHO Classification 1978</b>	<b>WHO Classification 1991</b>	<b>WHO Classification 2005</b>
WHO type I (well-differentiated keratinized SCC)	Squamous cell carcinoma	Keratinizing squamous cell carcinoma (SCC)
WHO type II (differentiated keratinized non-SCC)	Non-keratinizing carcinoma (a). Differentiated (b). Undifferentiated	Non-keratinizing carcinoma (a). Differentiated (b). Undifferentiated
WHO type III (undifferentiated carcinoma)		Basaloid squamous cell carcinoma
<b>Stages of NPC and treatment (Lee <i>et al.</i>, 2015)</b>		
<b>Stage I</b>	<b>Stage II, III, IVA and IVB</b>	<b>Stage IVC (distant metastasis)</b>
Definitive treatment  Radiotherapy to nasopharynx & Radiotherapy to neck	Concurrent chemotherapy and radiotherapy	Palliative chemotherapy  Radiotherapy to alleviate symptoms
IMRT to minimise dose to critical structure	IMRT to minimise dose to critical structure	Referral to palliative care/ palliative home care

### 2.1.7 Molecular dysregulation in NPC

Early event in NPC progression involves heterozygosity loss on chromosomes 9p and 3p (Chan *et al.*, 2000, 2002; Chattopadhyay *et al.*, 2017). Another early events in NPC tumourigenesis are the deletion and promoter hypermethylation of chromosomes 3p (*RASSF1*) and 9p (*p16 [CDKN2A]*) (Kwong *et al.*, 2002; Young and Rickinson, 2004). Gains on chromosomes 1q and 3q have also been reported in NPC. Oncogenes, such as phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (*PIK3CA*), ras (rat sarcoma) B cell CLL/lymphoma-2 B cell CLL/lymphoma-2, (*Bcl-2*), *CCND1* (cyclin D1), B lymphoma Mo-MLV insertion region 1 homolog, (*Bmi-1*) and Lymphotoxin beta receptor (*LTBR*) are overexpressed or mutated in NPC (Lu *et al.*, 1993; Hui *et al.*, 2005; Li *et al.*, 2011; Lo *et al.*, 2012; Bononi *et al.*, 2013; Cho *et al.*, 2020 Tsang *et al.*, 2020). The up-regulated expression of *PIK3CA* and *LTBR* contributes to NPC pathogenesis via the activation of multiple signalling pathways, such as PI3K/AKT (Lo *et al.*, 2012; Tsang *et al.*, 2020). Super-enhancer-associated oncogenic transcripts, including F3, BCAR1, TBC1D2, LDLR and RNA TP53TG1, are overexpressed in NPC and function to promote NPC (Jiang *et al.*, 2017).


Previous exome sequencing analysis revealed that NPC development can be influenced by the deletions and mutation of autophagic genes (*ATG2A*, *ATG7* and *ATG13*), chromatin modification genes (*ARID1A* and *BAP1*) and genes in the ERBB–PI3K pathway (*PIK3CA*, *ERBB2* and *ERBB3*) (Lin *et al.*, 2014a; Dai *et al.*, 2016). The activation of the ERBB–PI3K pathway due to genetic alterations aggravates NPC. Oncogenic *PIK3CA* is dysregulated in NPC because of mutations at p.Glu545Lys and p.His1047Arg (Lin *et al.*, 2014). *KRAS* and Akt are amplified, Gly12 is mutated and *PTEN* is deleted in NPC (Lin *et al.*, 2014). *TP53* and *CDKN2* alterations in NPC affect the G1/S transition in the cell cycle.

Mutations in the *FAT* gene family, including *FAT1*, *FAT2* and *FAT3*, has been reported in NPC (Lin *et al.*, 2014). Previous report stated that *TP53* is mutated in NPC (Yee-Lin *et al.*, 2018; Rampias,2020). *BAP1* is deleted and/or mutated in NPC; thus, *BAP1* encodes tumour suppressors that are lost during NPC pathogenesis (Lin *et al.*, 2014). *ARID1A* inhibits NPC cell proliferation by regulating the expression of p21<sup>WAF1</sup> (Guan *et al.*, 2011; Guan *et al.*, 2012). *ARID1A* depletion causes *MYC* overexpression; hence, *ARID1A* is the target of *MYC* (Lin *et al.*, 2014). In NPC, *SYNE1* mutation deregulates epithelial cell differentiation. *NOTCH* family genes are also deleted or mutated in NPC. *SYNE1* protein enhances the *NOTCH1*-dependent differentiation of the epidermis (Williams *et al.*, 2011).

Chronic inflammation accounts for about 25 % of the factors that cause cancers (Pervez Hussain and Harris, 2007; Murata, 2018). Chronic inflammation induces inflammatory and epithelial cells to produce ROS and reactive nitrogen species (RNS), which cause oxidative stress (Pinlaor *et al.*, 2004; Murata, 2018). Chronic inflammation damages lipids, proteins and nucleic acids through oxidative stress and leads to tissue damage. Tissue injury can activate stem or progenitor cells to regenerate tissues, but ROS and RNS from the inflamed area, damage the stem or progenitor cells and lead to the accumulation of mutations and the generation of more cancer stem cells (Ohnishi, *et al.*, 2013; Wang *et al.*, 2016; Murata, 2018). Stemness markers, such as *ALDH1A1* and *CD44v6*, have been detected in NPC tissues (Wang *et al.*, 2016). *ALDH1A1*- or *CD44v6*-positive NPC cells form 8-nitroguanine (inflammation-specific carcinogenic marker) through the reaction between nitric oxide and superoxide anions, which causes mutagenesis via oxidative stress (Kawanishi *et al.*, 2006; Wang *et al.*, 2016).

### 2.1.8 NPC pathogenesis model.

Persistent contact of the nasopharyngeal mucosa with lifestyle and environmental carcinogens induces DNA damage, leading to genetic alterations in the nasopharyngeal epithelial cells which stimulate the establishment of EBV infection (Yang et al., 2019). The process of transformation induces *p16* gene (*CDKN2A*) inactivation on chromosome 9 and *RASSF1* inactivation on chromosome 3 resulting in cyclin D1 over-expression or amplification chromosome 11 regions which allows for latent EBV infection as well as epigenetic and genetic changes (Figure 2.2). Abnormal methylation of *CDKN2A* and *RASSF1* are considered as early critical events of NPC tumorigenesis (Tsao et al 2014; Dai et al., 2016) Genetic/epigenetic changes facilitate and encourage EBV infection and cause inflammation and molecular alteration, which result in the malignant transformation of the nasopharynx epithelial cells (Figure 2.2).



**Figure 2.2 NPC pathogenesis model.** Loss of chromosomes 3p and 9p as well as inactivation of RASSF1A and CDKN2A are the early pathogenic events in NPC that promote hyperplasia or low-grade dysplasia. Genetic/epigenetic changes facilitate and encourage EBV infection and cause inflammation and molecular alteration, which result in malignant transformation and NPC carcinogenesis (Adapted from Tsao *et al* 2014).



### 2.1.9 Oxidative stress and cellular homeostasis

Oxidative stress is an abnormal cellular status that arises from the lack of antioxidant reserve against reactive oxygen species (ROS). Excessive ROS and elevated levels of active oxygen regulate ageing and the induction of diseases, such as cancer (Xu *et al.*, 2014). ROS includes hydroxyl radicals ( $\cdot\text{OH}$ ), free radicals (such as superoxide [ $\text{O}_2^{\cdot-}$ ]) and non-polar hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) molecules, which contribute to oxidative stress. High ROS levels mediate the oxidation of macromolecules, including proteins, DNA, and lipids, and ultimately cause cellular damage by altering intracellular redox homeostasis, inhibiting repair mechanisms, and inducing apoptotic signalling (Schieber *et al.*, 2014; Chen *et al.*, 2017). Evidence have shown that oxidative stress contributes to the induction of cell ageing and disease progression (pollina & Brunet, 2011; Chen *et al.*, 2017; Liguori *et al.*, 2018). Oxidative stress-mediated damage occurs in the form of mitochondrial dysfunction, lipid peroxidation, protein denaturation and DNA modifications (Liguori *et al.*, 2018).

At the transcription level, ROS oxidises the cysteine (Cys) residues of activator protein-1, hypoxia-inducible factor-1 alpha, p53 and NF- $\kappa$ B to alter their DNA-binding sites (Georgieva *et al.*, 2017). ROS oxidises methionine and Cys to generate sulfoxide and sulfonic acids, respectively, which change the tertiary structures of proteins by degradation, activation or inhibition (Grimsrud *et al.*, 2008; Morry *et al.*, 2017). Dysregulated cellular ROS generation can induce DNA damage or inactivate DNA repair mechanisms (Morry *et al.*, 2017). In cancer, the accumulation of DNA damage due to insufficient DNA repair mechanisms leads to gene mutation. This instability in the genome will activate oncogenes, which cause unregulated metabolic activities and reduce antioxidant production to increase intracellular ROS generation (Morry *et al.*, 2017).

## 2.2 Structure of STIM1

STIM1 IS a transmembrane protein type 1 which is made up of 685 amino acids. It comprises of EF hands with two  $\text{Ca}^{2+}$  binding sites, one disulfide linkage, numerous glycosylation sites, cytosolic localized coiled-coil domains, one sterile-alpha motif (SAM) domain in the luminal-domain, as well as lysine, proline, and serine rich regions (Soboloff *et al.*, 2012). One previous report revealed that STIM1 has two EF hand motifs in which one binds  $\text{Ca}^{2+}$  while the second one is 'hidden' and cannot bind  $\text{Ca}^{2+}$ . The motifs of EF-hand interact closely with SAM known as EFSAM to form a compact-domain (Figure 2.3). STIM1 senses a decreased  $\text{Ca}^{2+}$  levels in the ER via EF hand  $\text{Ca}^{2+}$  binding-motif, which increases the oligomerization of STIM1. The STIM1 EF hand domain has equilibrium dissociation-constant ( $K_d$ ) that ranges from 0.2–0.6 mM which is consistent with fluctuations in the ER  $\text{Ca}^{2+}$  levels (Gudlur *et al.*, 2018).  $\text{Ca}^{2+}$  signaling activates dynamic changes in the ER causing movement of the STIM1 transmembrane protein, which involves sensing of the  $\text{Ca}^{2+}$  concentration in the lumen, and direct contact with Orail  $\text{Ca}^{2+}$  pump near the plasma membrane



**Figure 2.3** Structure of STIM1 and its luminal domain. ER luminal domain of STIM1 showing the location of EF-hand domain (EF) and SAM domain (Adapted from Stathopoulos *et al.*, 2008).

### 2.2.1 STIM1 calcium signaling and cancer

STIM1 is a transmembrane protein encoded by the *STIM1* gene that is positioned in the ER and has a transmembrane domain (Jardin *et al.*, 2018). *STIM1* is a novel human gene mapped to the chromosome 11p15.5 region (Wang *et al.*, 2017; Ge *et al.*, 2019). Its protein regulates calcium homeostasis and intracellular calcium concentration (Wang *et al.*, 2017). STIM1 has N-termini that extend into the lumen of the ER and C-termini that extend into the cytosol. *STIM1*'s N-terminal senses  $\text{Ca}^{2+}$  concentration changes (Figure 2.4). Reduction in  $\text{Ca}^{2+}$  concentration leads to the activation of *STIM1*, which causes STIM1 to bind to ORAI1. The ORAI1 channels are localised to the puncta to induce  $\text{Ca}^{2+}$  influx into the cell and triggered by receptor-associated phospholipase C (PLC) activation to generate inositol triphosphate (IP3). IP3 induces the opening of IP3-responsive  $\text{Ca}^{2+}$  channels in the ER membrane to release ER-stored  $\text{Ca}^{2+}$  into the cytoplasm (Jardin *et al.*, 2018).

Persistent  $\text{Ca}^{2+}$  signals can come as  $\text{Ca}^{2+}$  spikes or oscillations that lead to recurring morphological changes due to proteolysis. STIM1 overexpression can cause epithelial-to-mesenchymal transition (EMT). EMT is a morphogenic process that induces the loss of epithelial features in cells to transform into mesenchymal features, which results in the loss of cell-to-cell contact, the loss of cell polarity and increased motility. EMT creates invasive status in tumour cells and prevents apoptosis and senescence in the cell. EMT is a morphological indication of metastasis. A scientific report associated STIM1-triggered  $\text{Ca}^{2+}$  influx with EMT (Chen *et al.*, 2011). A recent report showed that STIM1 is implicated in the tumour metastasis of colorectal cancer (CRC) (Zang *et al.*, 2016). STIM1 regulates cell proliferation, cell cycle, apoptosis and cell migration during human cancer development (Jardin *et al.*, 2018).

Previous work by Sun *et al.* on hypopharyngeal carcinoma indicates that silencing the *STIM1* gene inhibits tumour growth and promotes apoptosis and cell cycle arrest (Sun *et al.*, 2014, 2015). *STIM1* repression remarkably inhibits cell migration in prostate cancer and inactivates the PI3K/Akt pathway (Zhou *et al.*, 2017). *STIM1* regulates various cellular activities, such as gene transcription, hormone production and neurotransmitter release (Lao and Le, 2020). Numerous studies have reported that *STIM1* silencing can suppress cell proliferation and migration in many cancer types (Chen *et al.*, 2011; Yang *et al.*, 2013; Wang *et al.*, 2015; Tu *et al.*, 2016; Zhou *et al.*, 2017). *STIM1* helps in the developmental processes and functional activities of numerous cell types, such as myoblasts, lymphocytes, skeletal muscle cells, smooth muscle cells, neurons, and adipocytes (Wang *et al.* 2017).

Additionally, countless studies have shown that the down-regulated expression of *STIM1* can suppress cancer growth and progression in CRC, gastric cancer, breast cancer, prostate cancer, lung cancer and hepato-cellular carcinoma (Umemura *et al.*, 2014; Pei *et al.*, 2016; Wang *et al.*, 2017; Zhou *et al.*, 2017; Karacicek *et al.*, 2019). The mechanism of *STIM1* is shown in Figure 2.4. *STIM1* up-regulation increases  $\text{Ca}^{2+}$  influx and accelerates cancer progression (Chen *et al.*, 2013). Calcium ( $\text{Ca}^{2+}$ ) functions as an intracellular messenger that is crucial in cellular processes, such as proliferation and apoptosis (Abdul *et al.*, 2008). *STIM1* senses  $\text{Ca}^{2+}$  release from the ER and triggers  $\text{Ca}^{2+}$  loss from *STIM1* EF-hand, which induces *STIM1* oligomer formation. The oligomer interacts and activates ORAI1 (Kawasaki *et al.*, 2009).